

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 3681)**

**VOLUNTARY ANNOUNCEMENT  
PRESENTATION OF PRECLINICAL STUDIES OF  
ANTI-CGC ANTIBODY (hC2) AT SID ANNUAL MEETING 2026**

The board of directors (the “**Board**”) of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that results of the preclinical studies of its in-house developed novel Anti-CGC Antibody, a first-in-class humanised anti- $\gamma$ c antibody, hC2, in humanized animal models for alopecia areata (“**AA**”) and vitiligo, have been presented at the Society for Investigative Dermatology (“**SID**”) Annual Meeting 2026 on 14 May 2026 in Chicago, U.S.

**Title:** Anti- $\gamma$ c receptor hC2 ameliorates autoreactive T cell induced alopecia areata and vitiligo in preclinical animal models  
**Lead Author:** Chin Wai HUI, SinoMab BioScience Limited  
**Type:** Poster Presentation  
**Abstract Link:** [https://www.sidnet.org/wp-content/uploads/2026/05/SID\\_Chicago26\\_Abstract\\_Final\\_3.pdf](https://www.sidnet.org/wp-content/uploads/2026/05/SID_Chicago26_Abstract_Final_3.pdf)

Data reveals that hC2 effectively suppressed skin autoimmunity driven by autoreactive T cells by selectively modulating  $\gamma$ c-dependent cytokine signaling pathways. This mechanism is distinct from widely used JAK inhibitors, offering the potential for a differentiated immunomodulatory therapy for patients. In this study, researchers evaluated two humanized disease models established by transplanting human autoreactive T cells. In the alopecia areata (AA) model, hC2 administration significantly reduced hair loss ( $\rho < 0.001$ ); in the vitiligo model, it significantly reduced skin depigmentation ( $\rho < 0.05$ ). These therapeutic effects were dose-dependent. In regard to suppression of inflammatory response, the treatment was associated with reduced skin infiltration of helper/cytotoxic T cells ( $\rho < 0.01$ ), and attenuation of local skin and systemic inflammation ( $\rho < 0.05$ ). Disease-associated inflammatory markers were also significantly reduced following treatment ( $\rho < 0.001$ ). Combined with preliminary toxicology studies in non-human primates, hC2 demonstrated favorable tolerability, supporting its profile as a biologic with a differentiated immunomodulatory mechanism in the treatment of AA and vitiligo.

The common gamma chain ( $\gamma_c$ ) serves as a critical shared subunit for receptors of multiple cytokines (including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21), playing a pivotal role in immune cell development, activation, and homeostasis. Therapeutic strategies targeting  $\gamma_c$  aim to suppress aberrant immune responses by blocking the signal transduction of these pro-inflammatory cytokines.

We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.

### **About Anti-CGC Antibody (hC2)**

Anti-CGC antibody is an in-house developed, first-in-class humanised anti- $\gamma_c$  antibody. Our *in vitro* assays suggested that our antibody could suppress inflammation and autoimmunity driven by B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, AA and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration.

### **About SID**

The Society for Investigative Dermatology (SID) was founded in 1937 and is dedicated to advancing and promoting disciplines related to skin health and disease through education, advocacy, and the exchange of scientific information. The SID Annual Meeting is one of the most influential international academic conferences in the field of investigative dermatology, bringing together over a thousand scientists from around the world who are interested in dermatology, to jointly explore and discover the latest research findings based on laboratory, clinical, and translational studies. The 83rd Annual Meeting of the Society for Investigative Dermatology (SID) was held from 13 to 16 May 2026, in Chicago, USA.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize Anti-CGC Antibody (hC2) successfully.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 14 May 2026

*As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.*